In accordance with cell-based experiments, in vivo experiments have confirmed that fisetin (20, 40, and 80 μM) is able to counteract tumor growth in a 4T1 orthotopic mammary tumor model by reducing the activation of PI3K/Akt/mTOR signaling pathway [124]. This evidence concerns the gene AKT1 and breast cancer.